U.S. FDA Approves StemCyte Biologics License Application for …
Nov 28, 2024 · BALDWIN PARK, CA, USA I November 22, 2024 I StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug …
Timberlyne Therapeutics Launches with a $180 Million Series A …
Jan 10, 2025 · Mountainfield Venture Partners, a biopharmaceutical company creation firm, partners with Keymed Biosciences to form Timberlyne Therapeutics, accessing global …
Sangamo Therapeutics to Regain Full Rights to Hemophilia A …
Dec 31, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease …
Nov 20, 2024 · Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon’s lead drug NUZ-001 and its major active …
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for …
Oct 12, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
PipelineReview.com. Biopharmaceutical News & Clinical Trials
PipelineReview.com is powered by La Merie Business Intelligence For immediate assistance, please call us during business hours: Mon-Fri 10:00am - 05:00pm; GMT+01 La Merie …
Tagrisso approved in the EU for patients with unresectable EGFR …
Dec 23, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
Sorriso Pharmaceuticals Announces Positive Phase 1b Clinical Trial ...
Dec 20, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & …
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as …
Dec 21, 2024 · BRAFTOVI in combination with cetuximab and mFOLFOX6 is the first and only combination regimen with targeted therapy approved for use as early as first-line for patients …
Expression Therapeutics Announces Promising Phase 1 Results for ...
ATLANTA, GA, USA I December 11, 2024 I Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy — ET3 — for …